Brief: Inhibikase Therapeutics Announces Interim Three-Month Results From Chronic Toxicology Studies Of Its Oral C-Abl Kinase Inhibitor
04/10/2021 13:07
Oct 4 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES INTERIM THREE-MONTH
RESULTS
FROM CHRONIC TOXICOLOGY STUDIES OF ITS ORAL C-ABL KINASE
INHIBITOR, IKT-148009, IN DEVELOPMENT FOR TREATMENT OF
PARKINSON'S DISEASE
* INTERIM ANIMAL DATA INDICATE TOXICOLOGY PROFILE IMPROVES
WITH
EXTENDED DAILY ORAL DOSING OF IKT-148009
* RESULTS SUPPORT FURTHER CLINICAL EVALUATION OF IKT-148009
* PENDING FDA REVIEW, PLANNED PHASE 2A STUDY IN PARKINSON'S
DISEASE PATIENTS EXPECTED TO INITIATE IN 2022
Source text for Eikon: ID:nPn990h2za
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary